scholarly journals Aloe vera for Prevention of Acute Radiation Proctitis in Colorectal Cancer a Preliminary Randomized, Placebo-Controlled Clinical Trial

2021 ◽  
Author(s):  
Adeleh Sahebnasagh ◽  
Fatemeh Saghafi ◽  
Arash Ghasemi ◽  
Jafar Akbari ◽  
Abbas Alipour ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Clinical Trial ◽  
Aloe Vera ◽  
Acute Radiation ◽  
Radiation Proctitis ◽  
Controlled Clinical Trial

Aloe vera for Prevention of Acute Radiation Proctitis in Colorectal Cancer: A Preliminary Randomized, Placebo-Controlled Clinical Trial

2020 ◽  
Author(s):  
Ebrahim Salehifar ◽  
adeleh sahebnasagh ◽  
fatemeh saghafi ◽  
abbas alipour ◽  
Arash Ghasemi ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Radiation Therapy ◽  
Cancer Patients ◽  
Aloe Vera ◽  
Acute Radiation ◽  
Radiation Proctitis ◽  
Lower Probability ◽  
Rectal Pain ◽  
Colorectal Cancer Patients ◽  
Subject Differences

Abstract Background Acute radiation proctitis (ARP) is a common complication of radiation therapy (RT). This adverse effect in severe cases ultimately results in interruption of RT and poor outcome. Aloe vera contains multiple antioxidant and anti-inflammatory compounds This study was aimed to evaluate the preventive effects of Aloe vera in ARP in colorectal cancer.Method: twenty eligible colorectal cancer patients, who received radiation, were randomized to receive Aloe vera 3% ointment or placebo for six weeks. At each weekly visit, ARP symptoms were evaluated by Radiation Therapy Oncology Group (RTOG) and clinical presentation criteria. The lifestyle impact of the symptoms, depression and anxiety for assessment of psychosocial status of patients, and quantitative CRP were evaluated as secondary endpoints.Results there was a significant improvement in the symptom index for diarrhea and total RTOG scores and quantitative CRP levels (between-subject differences or group effect) (p < 0.05) in Aloe group. The overall time trend (within-subject differences or time effect) was statistically significant for rectal bleeding, rectal pain, total clinical scores, proctitis, cystitis, and total RTOG (P < 0.05) in Aloe vera group. The median lifestyle score improved significantly with Aloe vera. Intervention patients had a lower probability of presenting anxiety in their overall HAD scale during RT.Conclusion The use of topical formulation of Aloe vera 3% diminished the severity of ARP in colorectal cancer patients. Trial registration: Current Controlled Trials IRCT201606042027N6, registrations date: 2016-04-09.

Effect of aloe vera mouthwash on dental plaque and gingivitis indices in children: A randomized controlled clinical trial

2020 ◽  
Vol 30 (1) ◽  
pp. 1-8
Author(s):  
Doaa Mhd Adnan Alnouri ◽  
Chaza Kouchaji ◽  
Abdul Hakim Nattouf ◽  
Mohammad Moaffak A. AlSayed Hasan
Keyword(s):  
Clinical Trial ◽  
Dental Plaque ◽  
Aloe Vera ◽  
Controlled Clinical Trial ◽  
Randomized Controlled Clinical Trial ◽  
Randomized Controlled

scholarly journals Aloe vera for prevention of radiation-induced dermatitis: a self-controlled clinical trial

2013 ◽  
Vol 20 (4) ◽  
pp. 345 ◽  
Author(s):  
P. Haddad ◽  
F. Amouzgar-Hashemi ◽  
S. Samsami ◽  
S. Chinichian ◽  
M.A. Oghabian
Keyword(s):  
Clinical Trial ◽  
Aloe Vera ◽  
Controlled Clinical Trial ◽  
Radiation Induced

An open-label, randomized, controlled clinical trial to explore the curative effects between the treatment of capecitabine and andrographolide and the single capecitabine in the patients with pathological and/or histologic diagnosed unresectable, advanced, recurrent, and metastatic colorectal cancer.

2017 ◽  
Vol 35 (4_suppl) ◽  
pp. TPS819-TPS819 ◽  
Author(s):  
Yongqian Shu ◽  
Jing Sun ◽  
Peifen Cai ◽  
Weicheng Wang ◽  
Xiao Han ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Clinical Trial ◽  
Target Therapy ◽  
The Elderly ◽  
Control Group ◽  
Controlled Clinical Trial ◽  
High Dose ◽  
Randomized Controlled Clinical Trial ◽  
Open Label ◽  
Randomized Controlled

TPS819 Background: Colorectal cancer (CRC) is one of the most commonly diagnosed solid tumors worldwide. Current therapies for the treatment of CRC mainly comprise fluoropyromidine-based chemotherapies that are used individually or in combination with oxaliplatin or/with target therapy. Andrographolide, a natural diterpenoid from Andrographispaniculata, has been reported to exert antibacterial, antiviral, anti-inflammation and neuroprotectiveactivities. Our previous studies have proved that Andrographolide can inhibit tumor growth in mice at a relatively high dose(about 200 mg/kg).The aim of the study is to make a comparison of PFS, RR, and OS of the elderly CRC between the treatment of xeloda and andrographolide and the signal xeloda.We look forward to these findings highlight the potential possibility of using this natural, safe and relatively inexpensivecompound as potential adjunctive treatments in improving the overall treatment response of patients with CRC in future. Methods: This is an open-label, randomized, controlled clinical trial. Patients older than or equal to 65, by pathological and/or histologic diagnosed unresectable, advanced, recurrent andmetastatic CRC, will be enrolled. These patients’ tumors must be clearly measured by radiographic technology. All cases of chemotherapy patients randomly divided into two groups, experimental group (xeloda with andrographolide): xeloda: 1250mg/m2 , po bid, d1–14, q3w; andrographolide: 500mg, ivd qd, d1–14, q3w; control group (xeloda): 1250mg/m2, po bid, d1–14, q3w, 21d/cycle. After each 2 cycles, patients will be examined by imageological tests (CT and/or MRI) or tumour biomarkers (CEA and CA199) to estimate the curative effects. Until the tumor progression or after 6 cycles, patients will be removed from this study. PFS is set as the primary endpoint while secondary endpoints include overall survival (OS), overall response rate (ORR), and health-related quality of life (HRQoL). Recruitment has begun in Jan 2014 and about 52 patients has joined this study. Clinical trial information: NCT01993472.

Sign in / Sign up

Export Citation Format

Share Document